Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

NCT00022971 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: Apolizumab
BIOLOGICAL: Rituximab

Sponsor

National Cancer Institute (NCI)